ASCO 2021 | Advancing glioblastoma treatment options: viral therapy, LIIT and immunotherapy

Andrew Sloan, MD, Case Western Reserve University, Cleveland, OH, talks on the latest approaches under investigation for the treatment of glioblastoma. Oncolytic viral therapy is an exciting novel strategy, with numerous ongoing clinical trials. Glioblastoma is an aggressive cancer with poor overall survival and no standard of care in the recurrent setting. Viral therapies such as PVSRIPO are among the first to demonstrate a survival benefit, giving them the potential to change clinical practice with further development. Immunotherapy-based approaches are also gaining attention. For example, trials are assessing immunotherapy in combination with radiotherapy or laser interstitial thermal therapy (LITT). This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.